Search This Blog

Friday, June 29, 2018

Inovio started at buy by Piper


Inovio assumed with an Overweight at Piper Jaffray. Piper Jaffray analyst Christopher Raymond assumed coverage of Inovio Pharmaceuticals with an Overweight rating and $12 price target. The stock is “poised for upside” as investors are assigning little value to key programs like VGX-3100, in Phase 3 for the treatment of cervical dysplasia, and INO-5410, in Phase 1/2 for bladder cancer, Raymond tells investors in a research note. He views Inovio’s immunotherapy platform as differentiated with a number of key proof of concept data points in coming quarters. The analyst would be a buyer of the stock to levels approaching $12.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.